Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 6/20 | 0.41 |
| ▸ | HTR2B | P41595 | 5/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1973236 | 0.94 | HTR2C (0.45) | CDAHTR2CHTR2BTP53NPY5R | |
| SCHEMBL25307809 | 0.86 | CDA (0.46) | CDANOS3NOS1KDM4EGAA | |
| SCHEMBL10982543 | 0.86 | CDA (0.46) | CDANOS3NOS1KDM4EGAA | |
| SCHEMBL6082054 | 0.86 | CDA (0.46) | CDANOS3NOS1KDM4EGAA | |
| SCHEMBL726957 | 0.86 | HTR2C (0.40) | HTR2CHTR2BTP53NPY5RHTR2A | |
| SCHEMBL5951577 | 0.84 | CDA (0.38) | CDANOS3NOS1 | |
| Hydrochloric Acid SCHEMBL1438916 | 0.84 | HTR2C (0.39) | HTR2CHTR2BTP53NPY5RHTR2A | |
| SCHEMBL5827421 | 0.84 | CDA (0.44) | CDAHTR2CHTR2BNPY5RNOS3 | |
| SCHEMBL6531351 | 0.82 | NOS1 (0.42) | CDAHTR2CHTR2BNPY5RNOS3 | |
| SCHEMBL19271812 | 0.82 | CDA (0.42) | CDANPY5RNOS3NOS1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012176123-A1 | 3 - IMIDAZOLYL- INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2012-12-27 | — | — | WO | disclosed |
| US-7053213-B2 | Therapeutic heterocycles | ASTRAZENECA AB (SE) | 2006-05-30 | — | — | US | disclosed |
| US-20030187255-A1 | Therapeutic heterocycles | MILLER SCOTT CARSON (US) | 2003-10-02 | — | — | US | disclosed |
| US-6444809-B1 | ANTIHISTAMINES | ZENECA LIMITED (GB) | 2002-09-03 | — | — | US | disclosed |
| US-6124279-A | NEUROKININ A ANTAGONISTS, ANTIASTHMATIC AGENTS | ZENECA LIMITED (GB) | 2000-09-26 | — | — | US | disclosed |
| US-5990130-A | NOVEL 4-SUBSTITUTED PIPERIDINE DERIVATIVES WHICH ANTAGONIZE NEUROKININ; USEFUL IN TREATMENT OF ASMTHMA AND RELATED CONDITIONS | ZENECA LIMITED (GB) | 1999-11-23 | — | — | US | disclosed |
| US-5861392-A | NONPEPTIDE ANTAGONISTS OF NEUROKININ A USEFUL FOR THE TREATMENT OF ASTHMA | ZENECA LIMITED (GB) | 1999-01-19 | — | — | US | disclosed |
| EP-0714392-B1 | HETEROCYCLES USEFUL AS NEUROKININ ANTAGONISTS | ZENECA LTD (GB) | 1998-11-04 | — | — | EP | disclosed |
| US-5567700-A | USEFUL FOR TREATING ASTHMA | ZENECA LIMITED (GB) | 1996-10-22 | — | — | US | disclosed |
| EP-0714392-A1 | HETEROCYCLES USEFUL AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1996-06-05 | — | — | EP | disclosed |
| WO-1995005377-A1 | HETEROCYCLES USEFUL AS NEUROKININ ANTAGONISTS | ZENECA LIMITED (GB) | 1995-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187255-A1 | Therapeutic heterocycles | BDKRB2, TK2, TACR2 | CDA 2897/4885HTR2C 286/4885HTR2B 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.